<DOC>
	<DOCNO>NCT01114425</DOCNO>
	<brief_summary>The objective ass nature incidence drug intolerance observe new antiretroviral triple therapy , Truvada® [ 0-0-1 ] + Isentress® 400 mg tablet [ 1-0-1 ] , prescribe set treatment individual recent exposure risk transmission HIV infection compare result previous study conduct accord methodology , combination antiretrovirals .</brief_summary>
	<brief_title>Safety Study Isentress® + Truvada® Post-exposure Treatment HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Inclusion criterion age 18 year consultation immediately follow exposure risk transmission HIV infection ( le 48 hour , except case rape period may increase maximum 120 hour ) person capable understanding principle study give his/her inform consent Exclusion criterion subject recently expose risk transmission HIV infection source patient know infected HIV treat , whose therapeutic history justifies introduction PET propose study subject contraindication prescription Truvada® and/or Isentress® ( renal impairment , allergy , etc . ) subject previously treat phenytoin , phenobarbital rifampicin , since combination raltegravir contraindicated subject know infected hepatitis B virus , whether treat lamivudine subject refuse take part study pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>tolerability post exposure HIV infection prophylaxis</keyword>
</DOC>